Bactigras Paraffin Gauze Dressing – Antiseptic Chlorhexidine-Impregnated Wound Dressing

Description Chlorhexidine acetate is a white to pale cream microcrystalline powder, odourless or almost odourless. It is soluble (at 20ºC) in 55 parts of water and 15 parts of alcohol. Composition of Dressing : Chlorhexidine Acetate BP 0.5% in white soft paraffin BP. Indications BACTIGRAS is indicated for adjunctive treatment and prevention of infection in skin loss lesions, including wounds and burns. Precautions BACTIGRAS should not be used if the seal or wrapper is broken. Photosensitivity, hypersensitivity and contact eczema have been observed, but the incidence has been very low. Since its introduction on the market in the U.K., reports indicate that the tulle presentation of chlorhexidine acetate causes only slight skin irritation or sensitization and that there is no pain on application. As a topical preparation, there have been no reports of chlorhexidine acetate overdosage by a systemic route. Accidental systemic administration of chlorhexidine solutions has failed to yield any specific ill effects, which were attributed to chlorhexidine. Gastric lavage is indicated for acute ingestion of chlorhexidine solutions. BACTIGRAS dressing is for administration to adults and children; it may be changed daily but frequency of application will depend upon the clinical circumstances (average: every 2-4 days). It is intended that the dressing will be principally used on up to 15% body area wounds for adults, (10% body area wounds for children). Although there is insufficient evidence to establish the safety of more extensive use, such use on larger area wounds may be considered when in the opinion of the physician, the expected benefit outweighs the potential risks. (Reports indicate that chlorhexidine acetate 0.1% solutions have been used on body area wounds of up to 50% without ill effect). The dressing is to be applied directly to the wound surface, one layer only, with forceps, under sterile conditions. Duration of administration will range from a few days to several months in extreme cases, depending upon the nature and severity of the wound. Treatment should be continued until satisfactory healing has occurred or until the wound site is ready for grafting. The drug should not be withdrawn from the therapeutic regimen while there remains the possibility of infection unless overt infection occurs, requiring specific alternative therapy, or a significant adverse reaction occurs. BACTIGRAS should be stored flat under controlled room temperature ( < 25ºC). 2705 2706